Your browser doesn't support javascript.
loading
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.
Venner, C P; Gillmore, J D; Sachchithanantham, S; Mahmood, S; Lane, T; Foard, D; Rannigan, L; Gibbs, S D J; Pinney, J H; Whelan, C J; Lachmann, H J; Hawkins, P N; Wechalekar, A D.
Afiliação
  • Venner CP; 1] National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK [2] Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
  • Gillmore JD; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Sachchithanantham S; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Mahmood S; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Lane T; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Foard D; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Rannigan L; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Gibbs SD; 1] National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK [2] Department of Clinical Haematology, Manchester Royal Infirmary, Central Manchester University Hospitals, Manchester, UK.
  • Pinney JH; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Whelan CJ; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Lachmann HJ; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Hawkins PN; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
  • Wechalekar AD; National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
Leukemia ; 28(12): 2304-10, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25027514
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Amiloidose Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Amiloidose Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Canadá